Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus intravenous iron therapy in chronic kidney disease
IRCT20231003059605N1Phase 2Completed
- Sponsor
- Pak Emirates Military Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Iron in chronic kidney disease (CKD) and anaemia (2 arms), sponsored by Pak Emirates Military Hospital. Primary endpoints: Change in serum iron, Change in hemoglobin and 2 more. Started Jan 2023; status: completed.
02
Drugs
Iron
03
Conditions
chronic kidney disease (CKD)anaemia
Beyond the preview
Go deeper on IRCT20231003059605N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231003059605N1.